Aryl isonitrile compounds as a new class of potent, broad-spectrum antifungal compounds
申请人:Purdue Research Foundation
公开号:US10449174B2
公开(公告)日:2019-10-22
Invasive fungal infections present a formidable global public health challenge due to the limited number of approved antifungal agents and the emergence of resistance to the frontline treatment options, such as fluconazole. Three fungal pathogens of significant concern are Candida, Cryptococcus, and Aspergillus given their propensity to cause opportunistic infections in immunocompromised individuals. This disclosure provides a set of aryl isonitrile compounds that possess broad-spectrum antifungal activity primarily against species of Candida and Cryptococcus. The most potent derivatives are capable of inhibiting growth of these key pathogens at concentrations as low as 0.5 μM. Remarkably, the most active compounds exhibit an excellent safety profile and are non-toxic to mammalian cells even at concentrations up to 256 μM.
由于获批的抗真菌药物数量有限,而且对氟康唑等一线治疗药物出现了抗药性,因此侵袭性真菌感染给全球公共卫生带来了严峻的挑战。由于白色念珠菌、隐球菌和曲霉菌容易引起免疫力低下人群的机会性感染,因此这三种真菌病原体备受关注。本公开提供了一组具有广谱抗真菌活性的芳基异腈化合物,主要针对念珠菌和隐球菌。最有效的衍生物能够在低至 0.5 μM 的浓度下抑制这些主要病原体的生长。值得注意的是,最有效的化合物具有极佳的安全性,即使浓度高达 256 μM 也不会对哺乳动物细胞产生毒性。